Drugs / GSK2831781
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03965533 | Jun → Dec 2019 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02195349 | Jul 2014 → Mar 2018 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03893565 | May 2019 → May 2021 | ulcerative colitis | GlaxoSmithKline | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-01-21 | Immutep S.A.S. | Results Ulcerative Colitis Phase II Study of GSK2831781 Discontinued immutep.com ↗
The trial was stopped by GSK based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial’s Data Review Committee. |
| 2021-01-21 | Immutep S.A.S. | Results Immutep Quarterly Activities Report immutep.com ↗
As announced today, GSK has stopped its phase II clinical trial evaluating GSK2831781 (derived from Immutep’s IMP731 antibody) in ulcerative colitis based on the assessment of clinical data |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-01-21 | Immutep S.A.S. | Ulcerative Colitis Phase II Study of GSK2831781 Discontinued immutep.com ↗ |
| 2021-01-21 | Immutep S.A.S. | Immutep Quarterly Activities Report immutep.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2831781 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965533 ↗ |
| Action | Deplete | “using the depletion of LAG-3+ T-cells” NCT02195349 ↗ |
| Modality | Monoclonal antibody | “humanized Antibody Dependent Cell Cytotoxicity (ADCC) enhanced monoclonal afucosylated antibody” NCT02195349 ↗ |
| Route | Intravenous | “administered by IV” NCT02195349 ↗ |
| Target | LAG3 | “specific to the Lymphocyte Activation Gene-3 (LAG-3) protein” NCT02195349 ↗ |